Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

A5 Laboratories Inc. (AFLB.OB) Completes Acquisition of Contract Research (CRO) and Interferon Production Technology

Yesterday, A5 Laboratories Inc. announced that they completed the acquisition of the Contract Research (CRO) and Interferon production technology previously announced on May 7, 2010 from Vida Pharma, based in Montreal, Canada. A5 Laboratories plans to secure immediately the intellectual property related to the interferon production technology. They also are working to complete their plans for pilot scale production and commercialization of interferon products for human and veterinary applications.
Dr. Richard Azani, President and CEO of A5 Laboratories Inc. said, “We are very pleased to complete the acquisition of the CRO and Interferon production technology assets. We now have at our disposal the necessary assets to develop and commercialize novel biotechnology products.”

Additionally, with the acquisition of the CRO assets, they have established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector.

Headquartered in Lachine, Quebec, Canada, A5 Laboratories Inc. provides contract analytical, regulatory and product development services. Incorporated in Nevada on June 21, 2006, the Company services the pharmaceutical and biotechnology companies in North America. They utilize their research capabilities to license and acquire novel biotechnology products for development and commercialization.

The Company engages in the development and marketing of novel immun- therapeutic applications of a natural Gamma – Interferon (nG-IFN). These applications include the diagnostic, the prevention, and the treatment of various animal and human diseases.

Interferon (NYSE:IFN) is a type of protein called a cytokine. It is secreted by cells of the body during an infection and it can inhibit viruses from spreading to neighboring cells. It can aid in destroying cancerous cells. Interferon therapy takes advantage of these natural protective properties. Commercial interferon is used as a treatment for viral infections, such as hepatitis C, and as a treatment for certain cancers.

Interferon therapy is used to treat patients suffering from malignant melanoma that has spread to lymph nodes. It has been shown to reduce the rate of recurrence in patients with melanoma, and can be used to treat other cancers, mainly leukemia and lymphoma.

For more information visit:

Please see disclaimer on QualityStocks website:

Disclosure: no positions